Phase II Study of Imatinib Mesylate as Adjuvant Treatment in High-Relapse Risk Localized Gastrointestinal Stromal Tumors With c-Kit Mutation
Phase of Trial: Phase II
Latest Information Update: 29 Jul 2015
At a glance
- Drugs Imatinib (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Therapeutic Use
- 18 Apr 2013 Actual end date changed from Aug 2007 to Mar 2011 as reported by ClinicalTrials.gov.
- 28 Nov 2007 Status changed from recruiting to completed.
- 18 Nov 2006 New trial record.